Recent Updates
Recently added Catalysts
ORKA Positive Sentiment

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Key Takeaway: Oruka Therapeutics announced its participation in several upcoming healthcare conferences, including the Guggenheim and Stifel conferences. The company focuses on developing novel biologics for chronic skin diseases like plaque psoriasis. Presentations will occur from November 10 to November 18, 2026, with webcasts available for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Oruka is participating in multiple key healthcare conferences.
  • The company aims to set a new standard in chronic skin disease treatment.
  • Oruka's biologics may allow infrequent dosing for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
16.7%
average across 5 past catalysts
Cash runway
~99 mo
Low dilution risk
Lead asset
ORKA-002
Phase 2 · Plaque Psoriasis

Full Press Release Details

MENLO PARK, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its participation and presentation at multiple upcoming conferences:

Guggenheim 3rd Annual Healthcare Innovation Conference Date: November 10, 2026 Presentation Time: 11:00 AM EST

Stifel 2026 Healthcare Conference Date: November 11, 2026 Presentation Time: 4:00 PM EST

UBS Global Biopharma Conference Date: November 17, 2026 Presentation Time: 4:00 PM GMT

Jefferies Global Healthcare Conference Date: November 18, 2026 Presentation Time: 4:30 PM GMT

Webcasts and replays of Oruka’s presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Investor Contact: Alan Lada (650)-606-7911 alan.lada@orukatx.com

Frequently Asked Questions

What conferences will Oruka participate in?

Oruka will participate in the Guggenheim, Stifel, UBS, and Jefferies conferences.

When is the Guggenheim conference?

The Guggenheim conference is on November 10, 2026.

What is Oruka Therapeutics developing?

Oruka is developing biologics for chronic skin diseases.

How often can patients dose Oruka's treatments?

Patients may dose Oruka's treatments once or twice a year.

Last updated: Nov 3, 2026